cipralisant | 213027-19-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: cipralisant
• 英文别名: GT-2331；5-[(1R,2R)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1H-imidazole
• CAS: 213027-19-1
• 化学式: C₁₄H₂₀N₂
• 分子量: 216.326
• InChiKey: CVKJAXCQPFOAIN-VXGBXAGGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  cipralisant 以98的产率得到(1R,2R)-4-(2-ethynyl-cyclopropyl)-1-trityl-1H-imidazole
  参考文献：
  名称：

  J. Med. Chem. 1999, 42, 903-909

  摘要：

  DOI：
• 作为产物：
  描述：

  [(1R,2R)-2-(1-Trityl-1H-imidazol-4-yl)-cyclopropyl]-methanol 以90的产率得到cipralisant
  参考文献：
  名称：

  J. Med. Chem. 1999, 42, 903-909

  摘要：

  DOI：

文献信息

• ENZYME INHIBITORS
  申请人：Thormann Michael

  公开号：US20070244177A1

  公开（公告）日：2007-10-18

  There is dislosed herein compounds of formula (I), wherein: R 1 , R 2 , R 3 , R 4 and R 5 are defined throughout the description and the claims. The compounds of formula (I) are useful for the treatment of neurological diseases and neurodegenerative diseases, e.g. anxiety, depression, Alzheimer's disease etc.

  本文披露了公式（I）的化合物，其中：R1、R2、R3、R4和R5在描述和权利要求中有定义。公式（I）的化合物可用于治疗神经疾病和神经退行性疾病，例如焦虑、抑郁、阿尔茨海默病等。
• 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
  申请人：Gliatech, Inc.

  公开号：US06008240A1

  公开（公告）日：1999-12-28

  The present invention provides compounds having H.sub.3 histamine receptor antagonist activity of the general formula: ##STR1## R.sub.2 is a hydrogen or a methyl or ethyl group; R.sub.3 is a hydrogen or a methyl or ethyl group; n is 1, 2, 2, 3, 4, 5, or 6; and R.sub.1 is selected from the group consisting of (a) C.sub.3 to C.sub.8 cycloalkyl; (b) phenyl or substituted phenyl; (c) alkyl; (d) heterocyclic; (e) decahydronapthalene; and (f) octahydroindene; with the provisos that when X is H, A can be --CH.sub.2 CH.sub.2 --,--COCH.sub.2 --,--CONH--,--CON(CH.sub.3), CH.dbd.CH, --c.ident.c--,--CH.sub.2 --NH--, --CH.sub.2 --N(CH.sub.3)--,--CH(OH)CH.sub.2 --,--NH--CH.sub.2 --, --N(CH.sub.3)--CH.sub.2 --,--CH.sub.2 O--,--CH.sub.2 S--, and --NHCOO--; when X is NH.sub.2, NH(CH.sub.3), N(CH.sub.3).sub.2, OH, OCH.sub.3, CH.sub.3, SH, and SCH.sub.3 ; A can be --NHCO--, --N(CH.sub.3)--CO--, --NHCH.sub.2 --, --N(CH.sub.3)--CH.sub.2 --, --CH.dbd.CH--; --COCH.sub.2, --CH.sub.2 CH.sub.2 --,--CH(OH)CH.sub.2, or --C.ident.C--; and when R.sub.1 and X taken together denote a 5,6 or 6,6 saturated bicyclic ring structure X NH, O, or S and the pharmaceutically acceptable salts, and individual stereoisomers of compounds of structural formula (1.0) above. This invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with an effective amount of a compound of the above formula and a method of treating conditions in which antagonism of histamine H.sub.3 receptors may be of therapeutic importance.

  本发明提供了具有H.sub.3组胺受体拮抗活性的化合物，其通式为：##STR1##其中，R.sub.2是氢或甲基或乙基基团；R.sub.3是氢或甲基或乙基基团；n为1、2、2、3、4、5或6；R.sub.1选自以下组中的一种：(a) C.sub.3到C.sub.8的环烷基；(b) 苯或取代苯基；(c) 烷基；(d) 杂环基；(e) 十氢萘基；(f) 八氢萘基；但需满足当X为H时，A可以是--CH.sub.2 CH.sub.2 --，--COCH.sub.2 --，--CONH--，--CON(CH.sub.3)，CH.dbd.CH，--c.ident.c--，--CH.sub.2 --NH--，--CH.sub.2 --N(CH.sub.3)--，--CH(OH)CH.sub.2 --，--NH--CH.sub.2 --，--N(CH.sub.3)--CH.sub.2 --，--CH.sub.2 O--，--CH.sub.2 S--和--NHCOO--；当X为NH.sub.2，NH(CH.sub.3)，N(CH.sub.3).sub.2，OH，OCH.sub.3，CH.sub.3，SH和SCH.sub.3时，A可以是--NHCO--，--N(CH.sub.3)--CO--，--NHCH.sub.2 --，--N(CH.sub.3)--CH.sub.2 --，--CH.dbd.CH--，--COCH.sub.2，--CH.sub.2 CH.sub.2 --，--CH(OH)CH.sub.2或--C.ident.C--；当R.sub.1和X一起表示为5,6或6,6饱和双环环状结构X NH，O或S及其药学上可接受的盐，以及化合物的单体立体异构体。本发明还提供了包含药学上可接受的载体和上述式子化合物的有效量的药物组合物，以及治疗组胺H.sub.3受体拮抗可能具有治疗重要性的疾病的方法。
• Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
  申请人：Gliatech, Inc.

  公开号：US20030069295A1

  公开（公告）日：2003-04-10

  A method for the use of histamine H 3 receptor inverse agonists in the regulation of appetite and treatment of obesity is disclosed. Presently preferred inverse agonists are imidazole derivatives.

  使用组胺 H 3 受体反向激动剂调节食欲和治疗肥胖症的方法。目前优选的反向激动剂是咪唑衍生物。
• Design, Synthesis, and Structure−Activity Relationships of Acetylene-Based Histamine H₃ Receptor Antagonists
  作者：Syed M. Ali、Clark E. Tedford、Rosilyn Gregory、Michael K. Handley、Stephen L. Yates、Walter W. Hirth、James G. Phillips

  DOI：10.1021/jm980310g

  日期：1999.3.1

  New, potent, and selective histamine H-3 receptor antagonists have been synthesized by employing the use of (1) an appropriately positioned nonpolar acetylene spacer group, (2) either a two-carbon straight chain linker or a conformationally restricting trans-cyclopropane ring between the C-4 position of an imidazole headgroup and the acetylene spacer, and (3) a Topliss operational scheme for side-chain substitution for optimizing the hydrophobic domain. Compounds 9-18 are examples synthesized with the two-carbon straight chain linker, whereas 26-31 are analogues prepared by incorporation of the trans-(+/-)-cyclopropane at the C-4 position of an imidazole headgroup. Synthesis of both the (1R,2R)- and (1S,2S)-cyclopropyl enantiomers of the most potent racemic compound 31 (K-i = 0.33 +/- 0.13 nM) demonstrated a stereopreference in H-3 receptor binding affinity for the (1R,2R) enantiomer 32 (K-i = 0.18 +/- 0.04 nM) versus the (1S,2S) enantiomer 33 (K-i = 5.3 +/- 0.5 nM). (1R,2R)-4-(2-(5,5-Dimethylhex-1-ynyl)cyclopropyl)- imidazole (32) is one of the most potent histamine H-3 receptor antagonists reported to date.
• NOVEL INHIBITORS OF GLUTAMINYL CYCLASE
  申请人：Probiodrug AG

  公开号：EP1713780B1

  公开（公告）日：2012-01-18